Concepts (183)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adenocarcinoma | 2 | 2022 | 1013 | 0.540 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 785 | 0.510 |
Why?
|
| Diverticulum, Colon | 1 | 2014 | 4 | 0.440 |
Why?
|
| Adenomatous Polyps | 1 | 2014 | 11 | 0.440 |
Why?
|
| Colonic Polyps | 1 | 2014 | 73 | 0.400 |
Why?
|
| Veterans | 4 | 2022 | 1780 | 0.400 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 1001 | 0.400 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2022 | 121 | 0.400 |
Why?
|
| Colonoscopy | 1 | 2014 | 233 | 0.370 |
Why?
|
| Liver Neoplasms | 1 | 2022 | 1408 | 0.360 |
Why?
|
| Colonic Neoplasms | 1 | 2014 | 260 | 0.360 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2011 | 176 | 0.320 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 189 | 0.310 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2023 | 61 | 0.310 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2011 | 149 | 0.310 |
Why?
|
| Bronchoscopy | 3 | 2015 | 172 | 0.310 |
Why?
|
| Duodenum | 2 | 2020 | 97 | 0.290 |
Why?
|
| Lung | 3 | 2011 | 1570 | 0.260 |
Why?
|
| Middle Aged | 18 | 2022 | 28952 | 0.230 |
Why?
|
| Plasma Cells | 1 | 2025 | 57 | 0.230 |
Why?
|
| Influenza, Human | 1 | 2011 | 699 | 0.220 |
Why?
|
| Mediastinal Diseases | 1 | 2003 | 15 | 0.210 |
Why?
|
| Mammary Analogue Secretory Carcinoma | 1 | 2023 | 8 | 0.210 |
Why?
|
| Rhabdomyoma | 1 | 2003 | 16 | 0.200 |
Why?
|
| Antigens, Neoplasm | 1 | 2025 | 406 | 0.190 |
Why?
|
| Scalp | 1 | 2022 | 58 | 0.190 |
Why?
|
| Mouth Neoplasms | 1 | 2003 | 99 | 0.180 |
Why?
|
| Precancerous Conditions | 2 | 2014 | 254 | 0.180 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2025 | 335 | 0.170 |
Why?
|
| Male | 22 | 2022 | 65527 | 0.170 |
Why?
|
| Carcinoma | 1 | 2023 | 305 | 0.170 |
Why?
|
| Cell Degranulation | 1 | 2020 | 28 | 0.170 |
Why?
|
| Lung Neoplasms | 2 | 2025 | 1558 | 0.170 |
Why?
|
| Neoplasm Proteins | 1 | 2025 | 712 | 0.170 |
Why?
|
| Eosinophils | 1 | 2020 | 108 | 0.160 |
Why?
|
| Barrett Esophagus | 2 | 2014 | 343 | 0.160 |
Why?
|
| Dyspepsia | 1 | 2020 | 103 | 0.160 |
Why?
|
| Eosinophilia | 1 | 2020 | 86 | 0.160 |
Why?
|
| Endoscopy, Digestive System | 2 | 2016 | 147 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2015 | 2193 | 0.140 |
Why?
|
| Emphysema | 2 | 2009 | 67 | 0.140 |
Why?
|
| Humans | 27 | 2025 | 133269 | 0.140 |
Why?
|
| Biopsy, Needle | 4 | 2013 | 233 | 0.130 |
Why?
|
| Celiac Disease | 1 | 2016 | 57 | 0.120 |
Why?
|
| Granuloma, Giant Cell | 1 | 2015 | 12 | 0.120 |
Why?
|
| Salivary Glands, Minor | 1 | 2015 | 11 | 0.120 |
Why?
|
| Bone Marrow Diseases | 1 | 2015 | 41 | 0.120 |
Why?
|
| Public Health Surveillance | 1 | 2015 | 45 | 0.110 |
Why?
|
| Image-Guided Biopsy | 1 | 2015 | 43 | 0.110 |
Why?
|
| Klatskin Tumor | 1 | 2014 | 6 | 0.110 |
Why?
|
| Endosonography | 1 | 2015 | 81 | 0.110 |
Why?
|
| Gastritis | 1 | 2017 | 267 | 0.110 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2015 | 44 | 0.110 |
Why?
|
| Hernia, Hiatal | 1 | 2014 | 60 | 0.110 |
Why?
|
| Splenic Neoplasms | 1 | 2014 | 12 | 0.110 |
Why?
|
| Fatal Outcome | 2 | 2014 | 376 | 0.110 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2014 | 104 | 0.110 |
Why?
|
| Leukocytosis | 1 | 2014 | 48 | 0.110 |
Why?
|
| Hemangiosarcoma | 1 | 2014 | 46 | 0.100 |
Why?
|
| Female | 12 | 2022 | 71454 | 0.100 |
Why?
|
| Bile Duct Neoplasms | 1 | 2014 | 121 | 0.100 |
Why?
|
| Cholangiocarcinoma | 1 | 2014 | 121 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 312 | 0.100 |
Why?
|
| Lymph Nodes | 1 | 2015 | 395 | 0.100 |
Why?
|
| Esophagoscopy | 1 | 2013 | 163 | 0.100 |
Why?
|
| Gout | 1 | 2015 | 167 | 0.090 |
Why?
|
| Tracheal Neoplasms | 1 | 2012 | 21 | 0.090 |
Why?
|
| Thrombocytopenia | 1 | 2014 | 236 | 0.090 |
Why?
|
| Debridement | 1 | 2012 | 92 | 0.090 |
Why?
|
| Overweight | 1 | 2014 | 386 | 0.090 |
Why?
|
| Neurilemmoma | 1 | 2012 | 47 | 0.090 |
Why?
|
| Gastroesophageal Reflux | 1 | 2014 | 316 | 0.090 |
Why?
|
| Intensive Care Units | 1 | 2015 | 542 | 0.090 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 1364 | 0.090 |
Why?
|
| Lymphatic Metastasis | 3 | 2023 | 449 | 0.080 |
Why?
|
| Aged | 11 | 2020 | 21479 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 637 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2022 | 17554 | 0.080 |
Why?
|
| Anemia | 1 | 2014 | 349 | 0.080 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 86 | 0.080 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2009 | 77 | 0.080 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 162 | 0.080 |
Why?
|
| Esophageal Neoplasms | 1 | 2013 | 387 | 0.080 |
Why?
|
| Smoking | 3 | 2014 | 944 | 0.070 |
Why?
|
| Motor Activity | 1 | 2010 | 528 | 0.070 |
Why?
|
| Immunohistochemistry | 3 | 2013 | 1730 | 0.070 |
Why?
|
| Elastin | 1 | 2007 | 31 | 0.070 |
Why?
|
| Dendritic Cells | 1 | 2009 | 449 | 0.060 |
Why?
|
| Hepatitis C, Chronic | 1 | 2010 | 370 | 0.060 |
Why?
|
| Autoimmunity | 1 | 2007 | 181 | 0.060 |
Why?
|
| Hepatitis C | 1 | 2010 | 387 | 0.060 |
Why?
|
| Helicobacter Infections | 1 | 2014 | 1110 | 0.060 |
Why?
|
| Logistic Models | 2 | 2014 | 1864 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2010 | 728 | 0.060 |
Why?
|
| Macrophages, Alveolar | 1 | 2004 | 47 | 0.060 |
Why?
|
| Biomarkers, Tumor | 2 | 2023 | 1692 | 0.050 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2003 | 10 | 0.050 |
Why?
|
| Gingiva | 1 | 2023 | 12 | 0.050 |
Why?
|
| Th1 Cells | 1 | 2004 | 159 | 0.050 |
Why?
|
| Fiber Optic Technology | 1 | 2003 | 45 | 0.050 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 7137 | 0.050 |
Why?
|
| Mediastinal Neoplasms | 1 | 2003 | 43 | 0.050 |
Why?
|
| Pulmonary Emphysema | 1 | 2004 | 94 | 0.050 |
Why?
|
| Gene Fusion | 1 | 2023 | 61 | 0.050 |
Why?
|
| Lymphangioma | 1 | 2003 | 24 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 760 | 0.050 |
Why?
|
| Breast Neoplasms, Male | 1 | 2002 | 16 | 0.050 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2002 | 38 | 0.050 |
Why?
|
| Hemangioma | 1 | 2003 | 96 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2023 | 781 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2020 | 5199 | 0.050 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2007 | 631 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2023 | 236 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 2023 | 363 | 0.040 |
Why?
|
| Sex Factors | 2 | 2014 | 1350 | 0.040 |
Why?
|
| Prevalence | 2 | 2017 | 2631 | 0.040 |
Why?
|
| United States | 4 | 2020 | 11723 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2013 | 1254 | 0.040 |
Why?
|
| Adult | 7 | 2017 | 31648 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2017 | 3735 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 593 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2002 | 446 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 1965 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2025 | 3794 | 0.030 |
Why?
|
| Risk Factors | 3 | 2017 | 10954 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2002 | 1341 | 0.030 |
Why?
|
| Ethmoid Bone | 1 | 2015 | 8 | 0.030 |
Why?
|
| Elective Surgical Procedures | 1 | 2016 | 171 | 0.030 |
Why?
|
| Maxilla | 1 | 2015 | 39 | 0.030 |
Why?
|
| Uric Acid | 1 | 2015 | 109 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 5439 | 0.030 |
Why?
|
| Waist-Hip Ratio | 1 | 2014 | 60 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 168 | 0.030 |
Why?
|
| Hospitals, Veterans | 1 | 2016 | 365 | 0.030 |
Why?
|
| Radiography, Abdominal | 1 | 2014 | 49 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2015 | 333 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 401 | 0.030 |
Why?
|
| Time Factors | 2 | 2014 | 6544 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2013 | 280 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 2288 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 674 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 446 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 317 | 0.020 |
Why?
|
| Biopsy | 1 | 2015 | 1202 | 0.020 |
Why?
|
| Proton Pump Inhibitors | 1 | 2014 | 275 | 0.020 |
Why?
|
| Coffee | 1 | 2010 | 30 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2023 | 2762 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2013 | 477 | 0.020 |
Why?
|
| Equipment Design | 1 | 2012 | 604 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1514 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2009 | 133 | 0.020 |
Why?
|
| Data Collection | 1 | 2010 | 396 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2009 | 345 | 0.020 |
Why?
|
| Fatty Liver | 1 | 2010 | 215 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 1310 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 3043 | 0.020 |
Why?
|
| Mice | 1 | 2025 | 18935 | 0.020 |
Why?
|
| Registries | 1 | 2014 | 1582 | 0.020 |
Why?
|
| Anticholesteremic Agents | 1 | 2010 | 247 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 2952 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 3393 | 0.020 |
Why?
|
| Helicobacter pylori | 1 | 2014 | 1174 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2007 | 237 | 0.010 |
Why?
|
| Receptors, CXCR3 | 1 | 2004 | 23 | 0.010 |
Why?
|
| Receptors, Chemokine | 1 | 2004 | 47 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 2004 | 41 | 0.010 |
Why?
|
| Chemokines, CXC | 1 | 2004 | 38 | 0.010 |
Why?
|
| Chemokine CXCL10 | 1 | 2004 | 53 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2007 | 542 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2013 | 3719 | 0.010 |
Why?
|
| Animals | 1 | 2025 | 36215 | 0.010 |
Why?
|
| Inflammation | 1 | 2010 | 1557 | 0.010 |
Why?
|
| Liver | 1 | 2010 | 1859 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2002 | 118 | 0.010 |
Why?
|
| Antigens, Nuclear | 1 | 2002 | 56 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 3983 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2002 | 619 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 1378 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 1463 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2007 | 1770 | 0.010 |
Why?
|
| Disease Progression | 1 | 2004 | 2246 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2002 | 2125 | 0.010 |
Why?
|
| Adolescent | 1 | 2002 | 20547 | 0.000 |
Why?
|